Prevalence and mechanism of triazole resistance in *Aspergillus fumigatus* in a referral chest hospital in Delhi, India and an update of the situation in Asia

Anuradha Chowdhary¹*, Cheshta Sharma¹, Shallu Kathuria¹, Ferry Hagen² and Jacques F. Meis²,³

¹ Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India, ² Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands, ³ Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands

*Correspondence: Anuradha Chowdhary, Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, India dranuradha@hotmail.com

OPEN ACCESS

**Abstract**

*Aspergillus fumigatus* causes varied clinical syndromes ranging from colonization to deep infections. The mainstay of therapy of *Aspergillus* diseases is triazoles but several studies globally highlighted variable prevalence of triazole resistance, which hampers the management of aspergillosis. We studied the prevalence of resistance in clinical *A. fumigatus* isolates during 4 years in a referral Chest Hospital in Delhi, India and reviewed the scenario in Asia and the Middle East. *Aspergillus* species (*n* = 2117) were screened with selective plates for azole resistance. The isolates included 45.4% *A. flavus*, followed by 32.4% *A. fumigatus*, 15.6% *Aspergillus* species and 6.6% *A. terreus*. Azole resistance was found in only 12 (1.7%) *A. fumigatus* isolates. These triazole resistant *A. fumigatus* (TRAF) isolates were subjected to (a) calmodulin and β tubulin gene sequencing (b) in vitro antifungal susceptibility testing against triazoles using CLSI M38-A2 (c) sequencing of *cyp51A* gene and real-time PCR assay for detection of mutations and (d) microsatellite typing of the resistant isolates. TRAF harbored TR³⁴/L98H mutation in 10 (83.3%) isolates with a pan-azole resistant phenotype. Among the remaining two TRAF isolates, one had G54E and the other had three non-synonymous point mutations. The majority of patients were diagnosed as invasive aspergillosis followed by allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis. The Indian TR³⁴/L98H isolates had a unique genotype and were distinct from the Chinese, Middle East, and European TR³⁴/L98H strains. This resistance mechanism has been linked to the use of fungicide azoles in agricultural practices in Europe as it has been mainly reported from azole naïve patients. Reports published from Asia demonstrate the same environmental resistance mechanism in *A. fumigatus* isolates from two highly populated countries in Asia, i.e., China and India and also from the neighboring Middle East.

**Keywords:** triazole resistant *A. fumigatus*, TR³⁴/L98H, G54E, microsatellite typing, India, Asia
Introduction

Among the Aspergillus species, *Aspergillus fumigatus* is the leading etiologic agent of all forms of aspergillosis, which could be attributed to the ubiquitous presence of its thermo-tolerant spores that are refractory to adverse environmental conditions (Kwon-Chung and Sugui, 2013). *A. fumigatus*, in contrast to *Candida albicans*, has no reservoir in the immunocompetent population; thus, infections with *A. fumigatus* are generally environmentally acquired (Verweij et al., 2009; Chowdhary et al., 2013b). Furthermore, aspergillosis is associated with high morbidity and mortality in both immunocompetent and immunosuppressed populations primarily due to difficulties in early diagnosis or delay in recovery of the immune system (Kosmidis and Denning, 2015). Triazole antifungals, the competitive inhibitors of *cyp51A*, are preferred for prophylaxis and treatment of aspergillosis. However, failure of treatment with azoles and a steady increase in the occurrence of triazole resistant *A. fumigatus* (TRAF) isolates from environment as well as clinical settings has been reported (Denning et al., 1997; Mellado et al., 2007; Verweij et al., 2007; Rodriguez-Tudela et al., 2008; Snelders et al., 2008, 2009; Baddley et al., 2009; Howard et al., 2009; Arendrup et al., 2010; Mortensen et al., 2010, 2011; van der Linden et al., 2011, 2013; Burgel et al., 2012; Chowdhary et al., 2012a,b, 2013b, 2014a,b; Alastruey-Izquierdo et al., 2013; Badali et al., 2013; Bader et al., 2013; Escribano et al., 2013; Seyedmousavi et al., 2013; Prigitano et al., 2014; Spiess et al., 2014; Lavergne et al., 2015; Steinmann et al., 2015). The most common mechanism of triazole resistance has been linked to the TR34/L98H mutation with tandem repeat in the *cyp51A* promoter region combined with a single amino acid exchange of leucine 98 to histidine (Chowdhary et al., 2014c). Apparently, this mutated allele has spread throughout the *A. fumigatus* population and thus has been reported worldwide from patients as well as the environment (Mellado et al., 2007; Verweij et al., 2007; Rodriguez-Tudela et al., 2008; Snelders et al., 2008, 2009; Baddley et al., 2009; Howard et al., 2009; Mortensen et al., 2010, 2011; Lockhart et al., 2011; van der Linden et al., 2011, 2013; Burgel et al., 2012; Chowdhary et al., 2012a,b; Hamprecht et al., 2012; Jeurissen et al., 2012; Morio et al., 2012; Rath et al., 2012; Alastruey-Izquierdo et al., 2013; Bader et al., 2013; Escribano et al., 2013; Rocchi et al., 2014; Kidd et al., 2015; Steinmann et al., 2015). In addition several point mutations such as G54, G138, or M220 lead to disturbances in the docking ofazole drugsto *cyp51A* protein rendering azole resistant *A. fumigatus* phenotype (Diaz-Guerra et al., 2003; Mann et al., 2003; Mellado et al., 2004; Chen et al., 2005; Howard et al., 2006, 2009, 2013; Rodriguez-Tudela et al., 2008; Snelders et al., 2008; Albarrag et al., 2011; van der Linden et al., 2011). These mutations have been previously reported to occur *de novo* due to prolonged exposure of *A. fumigatus* isolates to azole antifungal drugs in clinical settings (Chen et al., 2005; Howard et al., 2009; Escribano et al., 2012). However, a recent study reports presence of *A. fumigatus* carrying G54 point mutation in the environment of Tanzania, Romania, and India suggesting that environment may predominately be the cause in acquisition of azole resistant isolates (Sharma et al., 2015). Also, non-*cyp51A* mediated mutations have been increasingly recognized in the development of azole resistance and are mainly reported from Manchester, UK (Bueid et al., 2010). We conducted a prospective study for the assessment of prevalence of TRAF and the underlying *cyp51A* mutations in clinical isolates of *Aspergillus* species collected during a 4-year (2011–2014) period in a referral Chest Hospital in Delhi, India and reviewed the reports on TRAF isolates from environmental and clinical sources from Asia and the neighboring Middle East.

Materials and Methods

Fungal Isolates and Their Phenotypic Characterization

During 2011–2014 a total of 8222 clinical samples were processed for fungal culture and microscopy collected from patients of our hospital and three neighboring referral hospitals included in Table 1. The clinical specimens included sputum, endotracheal aspirates, bronchial aspirates, bronchovascular lavages (BAL), bronchial tissues, fine needle aspiration biopsies, lung biopsies, nasal polyps, bone marrow aspirations, pleural fluid, bronchial plugs, and cerebrospinal fluid. The study was approved by the Institute’s Ethics Committee. All *Aspergillus* species cultured from the specimens were preliminarily identified based on colony color and morphology of the isolates on Czapek dox agar plates incubated at 28°C for 7 days. In order to investigate azole resistance in all of the *Aspergillus* species, they were screened on itraconazole (ITC, 4 μg/ml) and voriconazole (VRC, 1 μg/ml) supplemented Sabouraud dextrose agar (SDA) plates. *Aspergillus* isolates that exhibited growth on either of the antifungal plate were confirmed as *Aspergillus* species by amplification and sequencing of β-tubulin and calmodulin genes.

Antifungal Susceptibility Testing (AFST)

All resistant *A. fumigatus* were subjected to AFST against four standard medical triazoles, amphotericin B (AMB), echinocandins, and 10 commonly used azole fungicides using CLSI M38-A2 broth microdilution Clinical and Laboratory Standards Institute [CLSI] (2008). The drugs tested included ITC (Lee Pharma, Hyderabad, India, and Janssen Research Foundation, Beerse, Belgium), VRC (Pfizer Central Research, Sandwick, Kent, UK), isavuconazole (ISA, Basilea Pharmaceutica International AG, Basel, Switzerland), posaconazole (POS, Merck, Whitehouse Station, NJ, USA), AMB (Sigma–Aldrich, Germany), caspofungin (CAS, Merck), micafungin (MFG, Astellas Toyama Co. Ltd., Japan), and anidulafungin (AFG, Pfizer). The tested azole fungicides were bromuconazole, cyproconazole, difenoconazole, epoxiconazole, penconazole, tebuconazole, triadimefon, metconazole, hexaconazole (Rallis India, Mumbai, India), and tricyclazole (ChemNovia India, Mumbai, India). The AFST results were analyzed by using epidemiological cutoff values (ECVs) proposed by Espinel-Ingroff et al. (2011a,b, 2013) ITC, 1 μg/ml; VRC, 1 μg/ml; POS, 0.5 μg/ml; ISA,
TABLE 1 | Clinical characteristics of 12 patients with triazole resistant *Aspergillus fumigatus* (TRAF) isolates.

| Patient no. | Age/sex/year of isolation | Specimen | Institution | MICs (µg/ml)<sup>a,b</sup> | Mutation | Aspergillus disease | Underlying condition | Treatment | Outcome |
|-------------|---------------------------|----------|-------------|----------------------------|----------|---------------------|---------------------|-----------|---------|
| 1           | 60/M/2011                  | FNAB<sup>c</sup>/sputum | VPCI<sup>d</sup> | >16 ≥8 ≥8 ≥8 | TR<sub>34</sub>/L98H | IPA<sup>e</sup> | COPD<sup>f</sup>, Diabetes mellitus | VRC | Alive   |
| 2           | 65/M/2012                  | Lung biopsy | VPCI | >16 ≥8 2 ≥8 | TR<sub>34</sub>/L98H | IPA | Pulmonary adenocarcinoma | VRC | Died    |
| 3           | 38/F/2012                  | FNAB | Hospital 1<sup>e</sup> | >16 ≥8 2 ≥8 | TR<sub>34</sub>/L98H | IPA | Myelodysplastic syndrome | VRC | Died    |
| 4           | 19/F/2012                  | Endotracheal aspirate/tissue aspirate | VPCI | >16 8 8 1 | TR<sub>34</sub>/L98H | IPA | COPD, Tuberculosis | AMB | Died    |
| 5           | 26/F/2012                  | Resected sinus tissue | Hospital 2<sup>e</sup> | ≥16 >16 8 2 | TR<sub>34</sub>/L98H | IA rhinocerebral sinusitis | COPD | AMB | Died    |
| 6           | 52/M/2013                  | BAL<sup>c</sup> | Hospital 3<sup>j</sup> | >16 0.25 0.25 1 | G54E | CPA<sup>k</sup> | Preexisting tubercular cavities | VRC | Died    |
| 7           | 76/M/2014                  | Sputum | VPCI | 16 16 >8 4 | TR<sub>34</sub>/L98H | ABPA<sup>i</sup> | — | Systemic steroids | Died    |
| 8           | 55/M/2014                  | Bronchial aspirate | VPCI | ≥8 ≥8 ≥8 1 | TR<sub>34</sub>/L98H | ABPA | — | Systemic steroids | No follow up |
| 9           | 50/M/2014                  | BAL | VPCI | 16 ≥8 ≥8 ≥8 | TR<sub>34</sub>/L98H | CPA | Tuberculosis | VRC | Died    |
| 10          | 50/M/2014                  | BAL | VPCI | 16 2 4 0.06 | F46Y, D255E, M172V | CPA | — | AMB for 1 month, discharged on VRC | No follow up |
| 11          | 57/M/2014                  | Sputum | VPCI | ≥16 >16 >8 ≥8 | TR<sub>34</sub>/L98H | ABPA | — | Systemic steroids | No follow up |
| 12          | 60/M/2014                  | Sputum | VPCI | >16 >16 >8 >8 | TR<sub>34</sub>/L98H | ABPA | — | Systemic steroids | No follow up |

<sup>a</sup>MIC, minimum inhibitory concentration; ITC, itraconazole; VRC, voriconazole; ISA, isavuconazole; POS, posaconazole; AMB, amphotericin B; <sup>b</sup>Geometric mean MICs of all isolates against azole fungicides was 32 µg/ml except metconazole (3.8 µg/ml); <sup>c</sup>FNAB, fine needle aspiration biopsy; <sup>d</sup>VPCI, Vallabhbhai Patel Chest Hospital, Delhi; <sup>e</sup>IPA, invasive pulmonary aspergillosis; <sup>f</sup>COPD, chronic obstructive pulmonary disease; <sup>g</sup>Hospital 1, Cancer Referral Hospital, Delhi; <sup>h</sup>Hospital 2, General Medical Referral Hospital, Delhi; <sup>i</sup>BAL, bronchoalveolar lavage; <sup>j</sup>Hospital 3, Central Tuberculosis Hospital, Delhi; <sup>k</sup>CPA, chronic pulmonary aspergillosis; <sup>l</sup>ABPA, allergic bronchopulmonary aspergillosis.
1 μg/ml, AMB, 4 μg/ml, and CAS, 0.25 μg/ml (Pfaller et al., 2011).

**Mutation Analysis**

To gain insight into the mechanisms responsible for azole resistance in _A. fumigatus_, isolates were subjected to amplification and sequencing of cyp51A gene along with the promoter region (Sharma et al., 2015). The amplified product was purified followed by sequencing on an ABI 3130XL genetic analyzer (Applied Biosystems, Foster City, CA, USA) using the BigDye terminator kit (v3.1, RR-100; Applied Biosystems; Chowdhary et al., 2013a). DNA sequences were analyzed with Sequencing Analysis software version 5.3.1 (Applied Biosystems). Consensus sequences were made using BioEdit software (version 7.0.5.3; Hall, 1999). The sequences of the resistant _A. fumigatus_ strains were compared with the wild type susceptible reference _A. fumigatus_ strain (Af293). The mutations in the resistant strains were further confirmed by mixed format real time PCR analysis as described previously (Klaassen et al., 2010).

**Microsatellite Typing**

The genotypic relationship of the Indian resistant _A. fumigatus_ isolates with the isolates from Asia, Middle East, and Europe harboring various mutations in cyp51A gene was determined by microsatellite typing using a panel of nine short tandem repeats (STR) as described previously (de Valk et al., 2005). The amplification of three di-, tri-, or tetranucleotide repeat markers was carried out using three multiplex PCRs, namely, M2, M3, and M4, respectively, (de Valk et al., 2005). Repeat numbers in each marker was assigned using _A. fumigatus_ Af293 as reference. The STR data was imported to BioNumerics v5.1 software (Applied Maths, Sint-Martens-Latem, Belgium) for phylogenetic analysis. The dendrogram based on unweighted pair-group method with arithmetic mean (UPGMA) clustering using the Pearson correlation coefficient was generated. A total of 49 _A. fumigatus_ isolates from Asia, Middle East, and Europe were included as controls to evaluate the genetic differences with the _A. fumigatus_ isolates from India. The isolates from outside India were from following countries: China (clinical resistant, _n_ = 8), Iran (environmental resistant, _n_ = 5; environmental susceptible, _n_ = 4), Kuwait (clinical resistant, _n_ = 2; clinical susceptible, _n_ = 2; environmental resistant, _n_ = 8; environmental susceptible, _n_ = 2), France (clinical resistant, _n_ = 1), Germany (clinical resistant, _n_ = 7; clinical susceptible, _n_ = 1), the Netherlands (clinical resistant, _n_ = 2; environmental resistant, _n_ = 3), and Australia (clinical resistant, _n_ = 2; clinical susceptible, _n_ = 2). Also, Indian isolates (environmental resistant _n_ = 3; environmental susceptible _n_ = 6 and clinical susceptible _n_ = 3) collected during the previous study on resistant _A. fumigatus_ were included for comparison with the present clinical TRAF isolates from India (Chowdhary et al., 2012b).

**Results**

Overall, during a 4-year survey period, 25.7% of clinical samples harbored _Aspergillus_ species (_n_ = 2117). Out of these 2117 isolates, 45.4% (_n_ = 963) were _A. flavus_, followed by 32.4% (_n_ = 685) _A. fumigatus_, 15.6% (_n_ = 329) _Aspergillus_ species and 6.6% (_n_ = 140) _A. terreus_ (Kathuria et al., 2015). Barring 12 isolates of _A. fumigatus_ none of the other _Aspergillus_ species grew on SDA plates supplemented with ITC and/or VRC. Of these, 11 _A. fumigatus_ grew on both ITC and VRC supplemented SDA plates while a solitary isolate grew only on ITC plate. All the 12 resistant isolates were identified as _A. fumigatus sensu stricto_ by β-tubulin and calmodulin genes sequencing.

Of the 12 resistant _A. fumigatus_, 11 showed a pan-azole resistant phenotype exhibiting high MIC of all the triazoles, namely, ITC [geometric mean (GM) MIC, 16 μg/ml], VRC (GM MIC, 8 μg/ml), ISA (GM MIC, 6.34 μg/ml), and POS (GM MIC, 2.82 μg/ml). In contrast, a solitary _A. fumigatus_ isolate exhibited high MIC of only ITC (>16 μg/ml) and POS (1 μg/ml; Table 1). However, AMB (GM MIC, 0.4 μg/ml) and three echinocandins, namely, CAS, MFG, and AFG were active against all the resistant _A. fumigatus_ isolates with GM MICs of 0.13 μg/ml, 0.017 μg/ml, and 0.02 μg/ml, respectively. Further all TRAF uniformly revealed cross-resistance to all the azole fungicides (MICs>_32 μg/ml) tested excepting metconazole (MICs, 3.80 μg/ml).

Overall, 1.75% (12/685) of the clinical _A. fumigatus_ isolates were resistant. The major resistance mechanism observed among the eleven pan-azole resistant phenotype was _TR34/L98H_ mutation (_n_ = 10) and a solitary isolate exhibited three non-synonymous point mutations, namely, F46Y, D255E, and M172V. Another single point mutation, G54E, was observed in a solitary isolate that had high MICs to both ITC and POS.

The STR typing data revealed a single microsatellite complex (MC) among all the _TR34/L98H_ genotypes whereas solitary isolate each of G54E and non-synonymous mutant of _A. fumigatus_ represented two distinct genotypes (Figure 1). The _TR34/L98H_ MC was homogenous and shared all the nine loci except one isolate that differed at two loci (4A and 4C). Further to determine the genetic relatedness among the present Indian _TR34/L98H_ clinical isolates (_n_ = 10) comparison with Indian _TR34/L98H_ environmental isolates (_n_ = 3) collected from the previous study was done (Chowdhary et al., 2012b). Both the environmental and clinical _A. fumigatus_ isolates had an identical STR pattern. The genotypes of all Indian _TR34/L98H_ isolates were distinct from the _TR34/L98H_ strains of Chinese, Kuwait, Iran, and European isolates (Lockhart et al., 2011; Badali et al., 2013; Ahmad et al., 2014, 2015; Steinmann et al., 2015). However, environmental _A. fumigatus_ isolates from Kuwait (_n_ = 4) and Iran (_n_ = 5) were more closely related with Indian TRAFL isolates with similarity observed at 5–6 of the nine loci studied. Although the Chinese clinical TRAF isolates (_n_ = 8) also formed a separate cluster but unlike Indian isolates they were markedly heterogeneous exhibiting variable STR patterns. The STR typing data of the clinical Kuwait TRAF isolates (_n_ = 6) revealed homogeneity among them, however, when compared to Indian TRAF clinical isolates they showed differences at 6–7 loci (Ahmad et al., 2015).

The detailed clinical record of all patients whose clinical samples yielded TRAFL was retrieved from the database. The majority of patients were diagnosed as invasive aspergillosis (IA, _n_ = 5)
FIGURE 1 | Genotypic relationship of Indian Aspergillus fumigatus isolates (clinical resistant, n = 14; clinical susceptible, n = 3; environmental resistant, n = 3; environmental susceptible, n = 6) with isolates from Asia including China (clinical resistant, n = 8), Middle East including Iran (environmental resistant, n = 5; environmental susceptible, n = 4), and Kuwait (clinical resistant, n = 2; clinical susceptible, n = 2; environmental resistant, n = 8; environmental susceptible, n = 2), and Europe including France (clinical resistant, n = 1), Germany (clinical resistant, n = 7; clinical susceptible, n = 1), the Netherlands (clinical resistant, n = 6; environmental susceptible, n = 3), and Austria (clinical resistant, n = 2; clinical susceptible, n = 2). The dendrogram is based on a categorical analysis of nine microsatellite markers in combination with Unweighted Pair Group Method with arithmetic mean clustering. The scale bar indicates the percentage identity. The isolates VPCI 3352/14, VPCI 3355/14, VPCI 3500/12, and VPCI 3588/12 were serial isolates from two individual patients, respectively.

| Strain number | Source | Country | Genotype | Publication |
|---------------|--------|---------|----------|-------------|
| VPCI 3352/14 | India | Clinical | Resistant | Present study |
| VPCI 3355/14 | India | Clinical | Susceptible | Present study |
| VPCI 3500/12 | India | Clinical | Susceptible | Present study |
| VPCI 3588/12 | India | Clinical | Resistant | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/111 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Susceptible | Present study |
| VPCI 2434/112 | Kuwait | Clinical | Resistant | Present study |
| VPCI 3588/12 | India | Clinical | Susceptible | Present study |
followed by allergic bronchopulmonary aspergillosis (ABPA, \(n = 4\)) and chronic pulmonary aspergillosis (CPA, \(n = 3\)). The most common underlying condition among the IA patients was chronic obstructive pulmonary disease (COPD) in three patients and myelodysplastic syndrome and pulmonary adenocarcinoma in the remaining two patients, respectively. IA was defined as probable or proven according to the criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (Ascioglu et al., 2002; De Pauw et al., 2008). All cases of IA in the present study were proven cases and FNAB/lung biopsy or resected sinus tissue was positive for fungus and yielded \(A.\ fumigatus\) in culture. IPA (\(n = 4\)) was the most common manifestation and a solitary case had invasive rhino-cerebral sinusitis. All COPD patients who finally developed IA during the course of 5–10 years of illness had been admitted to the medical units or ICU repeatedly (4–9 episodes per year) for respiratory symptoms with severe airflow obstruction. All these patients were on systemic and inhaled steroids for a long period ranging from 10 to 12 years. Associated comorbidities like diabetes mellitus and tuberculosis were observed in two of the three COPD patients. Allergic aspergillosis manifesting as ABPA was diagnosed in four patients by a combination of clinical, mycoserologic, and radiological features (Agarwal et al., 2013). None of the ABPA patients diagnosed in the present study were on azoles when their culture grew TRAF. The third clinical entity was CPA, which was diagnosed by chronic duration of clinical symptoms (>3 months), progressive pulmonary lesions with or without cavitation, precipitating antibodies to \(A.\ fumigatus\) in serum, and mycological evidence of fungal presence. Further, none of the patients harboring identical \(TR34/L98H\) genotype (\(n = 10\)) admitted to the chest hospital (\(n = 8\)) in the present study had an overlapping time frame during their admission. Also, two patients harboring the same genotype were from two different hospitals in Delhi (Table 1).

Overall, the mortality was highest in IA (four of five patients) and CPA (two of three patients) and a solitary case of ABPA also had a fatal outcome. Among IA patients, VRC (6 mg/kg intravenous 12 hourly followed by 4 mg/kg and switched to oral 200 mg twice a day when clinically stable) was administered in three patients and two were started on AmB deoxycholate (1 mg/kg/day). All CPA patients were given VRC for 7–10 days before the antifungal susceptibility results were conveyed. The two CPA patients had severe lung involvement and the disease was fatal in both of them within 1 week. However, in one case therapy was switched to amphotericin B for one month followed by repeat BAL culture that yielded negative results for \(Aspergillus\) and the patient was discharged on oral VRC on follow up. However, patient failed to report for the follow up visits. The patients with ABPA in the present study were managed symptomatically and systemic steroids were the mainstay of therapy.

### Discussion

In the present study, we examined azole susceptibility and resistant mechanisms among \(A.\ fumigatus\) isolates from patients with bronchopulmonary aspergillosis in a referral Chest Institute, which caters to a vast population of Delhi and adjoining states of Uttar Pradesh, Haryana and also to far remote regions of India. The rate ofazole resistance in \(A.\ fumigatus\) isolates in our study was 1.75% (12/685) during a 4-year period, which is remarkably low compared to the high prevalence in Europe including UK (6.6–27.8%), the Netherlands (3.1–4.6%), and Germany (3.2%; Snelders et al., 2008; Howard et al., 2009; Bueid et al., 2010; van der Linden et al., 2011; Bader et al., 2013). In contrast in Spain, a lower prevalence rate (2.5%) of azole resistance in \(A.\ fumigatus\) complex has been reported suggesting that azole resistance has not yet uniformly spread in Europe (Escribano et al., 2013). \(TR34/L98H\) was the predominant resistance mechanism in 83.3% of the Indian TRAF isolates followed by G54E (\(n = 1\)) and a non-synonymous mutation (\(n = 1\)).

Short tandem repeats typing of the TRAF isolates demonstrated a single cluster, with a homogenous population. It is also worth mentioning here that the patients’ positive for TRAF isolates in the present study were both from Delhi, and other states namely West Bengal, Haryana, and Uttar Pradesh. These states previously have been found to harbor \(A.\ fumigatus\) isolates carrying \(TR34/L98H\) in soil samples (Chowdhary et al., 2012b). Notably the genotype detected in clinical isolates in this study was identical to the \(TR34/L98H\) genotype reported earlier from environmental samples from India and shared the identical nine loci, suggesting environmental origin of this major resistance mechanism (Chowdhary et al., 2012b). This is the first study outside the Netherlands revealing the possibility of acquisition of clinical isolates linked with the environment. However, in contrast to the heterogeneity observed in environmental and clinical isolates in the Netherlands (Klassen et al., 2012), the Indian TRAF in the present study had a homogenous population which was recently also confirmed with whole genome sequencing (Abdolrasouli et al., 2015).

**Table 2** summarizes the reports of TRAF isolation harboring mutations in the cyp51A gene from clinical and environmental sources in Asia and the neighboring Middle East. The initial reports describing azole resistance in clinical \(A.\ fumigatus\) isolates originated from Europe in the late 1990s followed by systematical investigations in several European countries which, reported prevalence, mechanism, and genomic aspects of TRAF (Mellado et al., 2007; Verweij et al., 2007; Rodriguez-Tudela et al., 2008; Howard et al., 2009; Mortensen et al., 2010; Burgel et al., 2012; Morio et al., 2012; Bader et al., 2013; Astvd et al., 2014; Fischer et al., 2014; Spiess et al., 2014; van der Linden et al., 2015). However, the first comprehensive report on the occurrence of TRAF isolates in Asia originated from China during 2008–2009 from the ARTEMIS global sentinel surveillance program demonstrating \(TR34/L98H\) resistance mechanism in 27.5% (8/29) \(A.\ fumigatus\) isolates (Lockhart et al., 2011; Table 2). In contrast, more recently few studies from Japan, described TRAF in clinical isolates but interestingly none of them exhibited \(TR34/L98H\) resistance mechanism, instead several SNPs and novel mutations, F332K and P216L were reported (Asano et al., 2011; Hagiwara et al., 2014). The single center study from Japan reported 5.2% (1/19) TRAF isolates harboring only G54E/R/W and I266N mutation (Tashiro et al., 2012a,b). Notably, a recent
TABLE 2 | Distribution of TRAF in clinical and environmental samples in Asia and Middle East harboring mutations in the Cyp51A gene.

| Country | Resistance mechanism | Source | Resistance rate (No. of resistant A. fumigatus / No. of A. fumigatus tested) | Reference |
|---------|----------------------|--------|---------------------------------------------------------------|-----------|
| China   | M220L, G54R          | Clinical | 4/6 (66.6%)\(^a\)                                           | Chen et al. (2005); Xu et al. (2010) |
|         | TR34/L98H            | Clinical | 8/29 (27.5%)                                                | Lockhart et al. (2011) |
|         | SNP                  | Environmental, Poultry | 11/175 (64%)                                           | Wang et al. (2014) |
| India   | TR34/L98H            | Clinical | 2/103 (1.9%)                                                | Chowdhary et al. (2012a) |
|         | TR34/L98H            | Environmental | 44/630 (7%)                                              | Chowdhary et al. (2012b) |
|         | TR34/L98H & TR46/Y121F/T289A | Environmental | 8/126 (6.3%)                                             | Chowdhary et al. (2014a) |
|         | TR34/L98H & GS4E     | Environmental | 4/5 (80%)                                                   | Sharma et al. (2015) |
| Iran    | TR34/L98H            | Clinical | 4/124 (3.2%)                                                | Seyedmousavi et al. (2013) |
|         | TR34/L98H            | Environmental | 5/41 (12.1%)                                            | Badali et al. (2013) |
| Japan   | F332K                | Clinical | 1/19 (5.2%)                                                 | Asano et al. (2011) |
|         | GS4E/R/W and I266N   | Clinical | 12/196 (6.1%)                                               | Tashiro et al. (2012a; 2012b) |
| Kuwait  | P218L                | Clinical | 1/8 (12.5%)                                                 | Hagiwara et al. (2014) |
|         | TR34/L98H            | Environmental | 8/115 (7%)                                               | Ahmad et al. (2014) |
|         | TR34/L98H            | Environmental | 1/50 (2%)                                                  | Ahmad et al. (2015) |
|         | TR34/L98H            | Environmental | 2/16 (12.5%)                                              | Ahmad et al. (2015) |
| Taiwan  | Not mentioned\(^b\) | Clinical | 2/40 (5%)                                                    | Hsieh et al. (2005) |

\(^a\)Serial isolates from a patient suffering from lung aspergilloma; \(^b\)SNP single nucleotide polymorphisms such as F46Y, M172V, N248T, N248K, D255E, and E427K also present in susceptible A. fumigatus strains were detected; \(^c\)total no. of A. fumigatus obtained from French and Chinese avian farms; \(^d\)The mutation in cyp51A gene was not investigated.

study on environmental sampling of air from a pumpkin farm sprayed with azole fungicides, at Nihon University, Japan was carried out by using an outdated and less efficacious settle plate method and reported no azole resistance in 50 A. fumigatus isolates (Kano et al., 2015). The lack of isolation of TRAF could be attributed to not adopting a highly efficacious sampling method such as using an air sampler and to the low number of isolates tested for resistance resulting in false rates of TRAF prevalence in the environment. The possibility of missing resistance was recently also highlighted in the SCARE study (van der Linden et al., 2015). Further, planned studies with wider coverage areas and different sources such as soil samples, air, wooden debris etc., should be undertaken for finding out the true prevalence of TRAF isolates. In India, a comprehensive wider environmental survey covering north, south, and eastern India analyzed 486 environmental samples comprising soil from flowerbeds of nurseries, surrounding parks of hospitals, cotton trees, tea gardens, paddy fields, soil containing bird excreta, and decayed wood of tree trunks revealed 7% TRAF isolates in the environment carrying TR34/L98H mutation (Chowdhary et al., 2012b). Also, a recently described VRC resistant TR46/Y121F/T289A mechanism was observed in environmental A. fumigatus isolates from agricultural fields in India (Chowdhary et al., 2014a). Barring the solitary environmental report on TR46/Y121F/T289A mechanism from India none of the clinical or environmental samples from Asia has yet documented the occurrence of A. fumigatus isolates carrying this mechanism so far. However, considering the presence of this new resistant mechanism in the environment of India it may be anticipated that in future it may spread to the neighboring Asian countries. In addition to the above-discussed reports on triazole resistance in Asia, the neighboring Middle East countries, Iran, and Kuwait had reported 12.2 and 7% TRAF carrying TR34/L98H resistance in the environment, respectively, (Badali et al., 2013; Ahmad et al., 2014). A similar range of resistance prevalence of 3.2 and 12.5% TR34/L98H A. fumigatus isolates was observed in clinical samples from CPA and ABPA patients from Iran and Kuwait, respectively, (Seyedmousavi et al., 2013; Ahmad et al., 2015). Based on the fact that the Indian TRAF isolates exhibited a distinct cluster away from the Chinese TR34/L98H isolates, it may be suggested that resistance among the A. fumigatus strains across Asia has evolved from separate strains and not from a common resistant ancestor, which may have spread worldwide.

It is also pertinent to mention that the high rates of triazole resistance in Europe as compared to Asia could be due to environmental factors or more so by frequent use of azoles in clinical settings and in the environment. Azole fungicides are extensively used in agriculture for crop protection to control mildews and rusts of grains, fruits, vegetables, and also for preservation of materials like wood etc. Geographically, Europe is the dominant market where fungicide usage is significantly high in production of fruits and vegetables along with wheat and vinegar (Stensvold et al., 2012). Thus, the reports of high resistance rates in environmental A. fumigatus isolates from the Netherlands, Belgium, UK, and Germany can be attributed to higher fungicide usage. Similarly, the absence or very low prevalence of triazole resistance in A. fumigatus in the USA could possibly be due to the low usage of fungicides in the USA as compared to Europe\(^1\). Notably, triazole resistance was screened among 1026 A. fumigatus isolates from

\(^1\)http://ec.europa.eu/food/fs/sc/ssc/out278en.pdf
22 states of USA and none had TR34/L98H mutation (Pham et al., 2014). In India, the crop protection chemicals account for ~2% of the total chemicals market and currently India is the second largest manufacturer of pesticides in Asia, second only to Japan1. Among different classes of pesticides used in India the percent share of insecticides (60%) is highest followed by fungicides (19%), herbicides (16%), biopesticides (3%), and others (3%). Per capita consumption of crop protection products in India is 0.6 kg/ha compared to 16 kg/ha in Taiwan, 13 kg/ha in China, and 12 kg/ha in Japan2. Finally, the environmental resistance mechanism in *A. fumigatus* isolates have been reported from two highly populated countries in Asia, i.e., China and India. Further, the environment of agricultural fields in India has been harboring variable *cyp51A* mediated resistant patterns in *A. fumigatus* isolates, which are continuously exposed to agricultural azole fungicides. It is emphasized that in depth analysis of azole resistance in *A. fumigatus* isolates in both clinical laboratories and environmental settings is required to prevent its spread and emergence in neighboring Asian countries.

**Acknowledgments**

This work was supported in part by a research grant from University Grants Commission Research Fellowship, India (F.2-15/2003 SA-I) and Indian Council of Medical Research (5/3/3/26/2010-ECD-I), Government of India, New Delhi, India. We are grateful to Paul E. Verweij (Radboud University Medical Centre, Nijmegen, the Netherlands) for providing several fungicides (bromuconazole, cyproconazole, difenoconazole, epoxiconazole, penconazole, tebuconazole, triadimefon, metconazole). We acknowledge Rallis India, India, and Cheminova India, for kindly providing us hexaconazole and tricyclazole fungicides.

---

References

Abdolrasoulia, A., Rhodes, J., Beale, M. A., Hagen, F., Rogers, T. R., Chowdhary, A., et al. (2015). Genomic context of azole-resistance mutations in *Aspergillus fumigatus* using whole-genome sequencing. *mBio, 6* (in press).

Agarwal, R., Chakrabarti, A., Shah, A., Gupta, D., Meis, J. F., Guleria, R., et al. (2013). Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin. Exp. Allergy, 43*, 850–873. doi: 10.1111/cea.12141

Ahmad, S., Joseph, L., Hagen, F., Meis, J. F., and Khan, Z. (2015). Concomitant occurrence of itraconazole-resistant and -susceptible strains of *Aspergillus fumigatus* in routine cultures. *J. Antimicrob. Chemother., 70*, 412–415. doi: 10.1093/jac/dku410

Ahmad, S., Khan, Z., Hagen, F., and Meis, J. F. (2014). Occurrence of triazole-resistant *Aspergillus fumigatus* with TR34/L98H mutations in outdoor and hospital environment in Kuwait. *Environ. Res., 133*, 20–26. doi: 10.1016/j.envres.2014.05.009

Alastreú-Isquierdo, A., Mellado, E., Pélaz, T., Pemán, J., Zapico, S., Álvarez, M., et al. (2013). Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). *Antimicrob. Agents Chemother., 57*, 3380–3387. doi: 10.1128/AAC.00383-13

Albarrag, A. M., Anderson, M. J., Howard, S. J., Robson, G. D., Warn, P. A., Sanglard, D., et al. (2011). Interrogation of related clinical pan-azole-resistant *Aspergillus fumigatus* strains: G138C, Y431C, and G434C single nucleotide polymorphisms in *cyp51A*, upregulation of *cyp51A*, and integration and activation of transposon *Atf1* in the *cyp51A* promoter. *Antimicrob. Agents Chemother., 55*, 5113–5121. doi: 10.1128/AAC.00517-11

Arendrup, M. C., Navidiou, E., Mortensen, K. L., Snelders, E., Frimodt-Møller, N., Khan, H., et al. (2010). Development of azole resistance in *Aspergillus fumigatus* during azole therapy associated with change in virulence. *PLoS ONE, 5*, e10080. doi: 10.1371/journal.pone.0001080

Asano, M., Kano, R., Makimura, K., Hasegawa, A., and Kamata, H. (2011). Molecular typing and in-vitro activity of azoles against clinical isolates of *Aspergillus fumigatus* and *A. niger* in Japan. *J. Infect. Chemother., 17*, 483–486. doi: 10.1007/s10156-010-0202-1

Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crookaert, F., et al. (2002). Defining opportunistic invasive fungal infections in immuno-compromised patients with cancer and hematopoietic stem cell transplants: an international consensus. *Clin. Infect. Dis., 34*, 7–14. doi: 10.1086/323335

Astvod, K. M., Jensen, R. H., Hassan, T. M., Mathiasen, E. G., Thomsen, G. M., Pedersen, U. G., et al. (2014). First detection of TR46/Y121F/T289A and TR34/L98H alterations in *Aspergillus fumigatus* isolates from azole-naive patients in Denmark despite negative findings in the environment. *Antimicrob. Agents Chemother., 58*, 5096–5101. doi: 10.1128/AAC.02855-14

Badali, H., Vaezi, A., Haghani, I., Yazdananparast, S. A., Hedayati, M. T., Mousavi, B., et al. (2013). Environmental study of azole-resistant *Aspergillus fumigatus* with TR34/L98H mutations in the cyp51A gene in Iran. *Mycoenes, 56*, 659–663. doi: 10.1111/myc.12089

Baddley, J. W., Marr, K. A., Andes, D. R., Walsh, T. J., Kaufman, C. A., Kontoyiannis, D. P., et al. (2009). Patterns of susceptibility of *Aspergillus* isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. *J. Clin. Microbiol., 47*, 3271–3275. doi: 10.1128/JCM.00854-09

Bader, O., Weig, M., Reichard, U., Lugert, R., Kuhns, M., Christner, M., et al. (2013). cyp51A-based mechanisms of *Aspergillus fumigatus* azole drug resistance present in clinical samples from Germany. *Antimicrob. Agents Chemother., 57*, 3513–3517. doi: 10.1128/AAC.00167-13

Beuea, A., Howard, S. J., Moore, C. B., Richardson, M. D., Harrison, E., Bowyer, P., et al. (2010). Azole antifungal resistance in *Aspergillus fumigatus*: 2008 and 2009. *J. Antimicrob. Chemother., 65*, 2116–2118. doi: 10.1093/jac/dkg279

Burgel, P. R., Baixench, M. T., Amsellem, M., Audureau, E., Chapron, J., Kanaan, R., et al. (2012). High prevalence of azole-resistant *Aspergillus fumi- gatus* in adults with cystic fibrosis exposed to itraconazole. *Antimicrob. Agents Chemother., 56*, 869–874. doi: 10.1128/AAC.01077-11

Chen, J., Li, H., Li, R., Bu, D., and Wan, Z. (2005). Mutations in the cyp51A gene and susceptibility to itraconazole in *Aspergillus fumigatus* serially isolated from a patient with lung aspergilloma. *J. Antimicrob. Chemother., 55*, 31–37. doi: 10.1093/jac/dkh307

Chowdhary, A., Agarwal, K., Kathuria, S., Singh, P. K., Roy, P., Gaur, S. N., et al. (2013a). Clinical significance of filamentous basidiomycetes illustrated by isolates of the novel opportunist *Ceriporia lacera* from the human respiratory tract. *J. Clin. Microbiol., 51*, 585–590. doi: 10.1128/JCM.02943-12

Chowdhary, A., Kathuria, S., Xu, J., and Meis, J. F. (2013b). Emergence of azole-resistant *Aspergillus fumigatus* strains due to agricultural azole use creates an increasing threat to human health. *PLoS Pathog., 9*, e1003633. doi: 10.1371/journal.ppat.1003633

Chowdhary, A., Kathuria, S., Randhawa, H. S., Gaur, S. N., Klaassen, C. H., and Meis, J. F. (2012a). Isolation of multiple-triazole-resistant *Aspergillus fumi- gatus* strains carrying the TR34/L98H mutations in the cyp51A gene in India. *J. Antimicrob. Chemother., 67*, 362–366. doi: 10.1093/jac/dkl443

Chowdhary, A., Kathuria, S., Xu, J., Sharma, C., Sundar, G., Singh, P. K., et al. (2012b). Clonal expansion and emergence of environmental multiple-triazole-resistant *Aspergillus fumigatus* strains carrying the TR34/L98H mutations in the cyp51A gene in India. *PLoS ONE, 7*, e52871. doi: 10.1371/journal.pone.0052871

---

2 http://www.fcci.com/spdocument/20292/petro1.pdf
Hall, T. A. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids. Symp. Ser. 41, 95–98. doi:10.14601/Phytopathol_Mediter.1499861.29

Hampecht, A., Buchheidt, D., Vehreschild, J. J., Cornely, O. A., Spiess, B., Plum, G., et al. (2012). Azole-resistant invasive aspergillosis in a patient with acute myeloid leukemia in Germany. Euro. Surveill. 17, 20262.

Howard, S. J., Cerar, D., Anderson, M. J., Albargh, A., Fisher, M. C., Pasqualotto, A. C., et al. (2009). Frequency and evolution ofazole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15, 1068–1076. doi:10.3203/eid1507.090943

Howard, S. J., Lass-Flörl, C., Cuenca-Estrella, M., Gomez-Lopez, A., and Arendrup, M. C. (2013). Determination ofisavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob. Agents Chemother. 57, 5426–5431. doi:10.1128/AAC.01111-13

Howard, S. J., Webster, I., Moore, C. B., Gardiner, R. E., Park, S., Perlin, D. S., et al. (2006). Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28, 450–453. doi:10.1016/j.ijantimicag.2006.08.017

Hsueh, P. R., Lau, Y. J., Chuang, Y. C., Wan, J. H., Huang, W. K., and Shyr, J. M. (2005). Antifungal susceptibility of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveil lance of multicenter antifungal resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother. 49, 512–517. doi:10.1128/AAC.49.2.512-517.2005

Jeurissen, A., Cooreman, S., Van Kerckhoven, W., Van Leemput, J., Vanhove, P., Lagrou, K., et al. (2012). Invasive pulmonary aspergillosis due to a multi-azole resistant Aspergillus fumigatus. Acta Clin. Belg. 67, 46–48.

Kano, R., Kohata, E., Tateishi, A., Murayama, S. Y., Hirose, D., Shibata, Y., et al. (2015). Does farm fungicide use induce azole resistance in Aspergillus fumigatus? Med. Mycol. 53, 174–177. doi:10.1093/amy/myu076

Kathuria, S., Sharma, C., Singh, P. K., Agarwal, P., Agarwal, K., Hagen, F., et al. (2015). Molecular epidemiology and in-vitro antifungal susceptibility of Aspergillus terreus species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing. PLoS ONE 10:e0118997. doi:10.1371/journal.pone.0118997

Kidd, S. E., Goeeman, E., Meis, J. F., Slavin, M. A., and Verweij, P. E. (2015). Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses 58, 350–355. doi:10.1111/mic.12324

Klaassen, C. H., de Valk, H. A., Curfs, I. M., Muehlethaler, K., Mouton, J. W., and DePauw, B., Walsh, T. J., Donnelly, P. A., Parmegiani, R. M., Wei, S. Q., Mendrick, C. A., Li, X., Loebenberg, D., et al. (2012). A point mutation in the 14-alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47, 1120–1124. doi:10.1128/AAC.47.3.1120-1124.2003

Kosmidis, C., and Denning, D. W. (2015). The clinical spectrum of pulmonary aspergillosis. Thorax 70, 270–277. doi:10.1136/thoraxjnl-2014-206291

Kwon-Chung, K. J., and Sugui, J. A. (2013). Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen? PLoS Pathog. 9:e1003743. doi:10.1371/journal.ppat.1003743

Lavergne, R. A., Morio, F., Favenec, L., Dominique, S., Meis, J. F., Gargala, G., et al. (2015). First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France. Antimicrob. Agents Chemother. (accepted). doi:10.1128/AAC.00127-15

Lockhart, S. R., Frade, J. P., Eiteren, K. A., Pfaller, M. A., Diekema, D. J., and Balajee, S. A. (2011). Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/198H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55, 4465–4468. doi:10.1128/AAC.00185-11

Mann, P. A., Parmegiani, R. M., Wei, S. Q., Mendrick, C. A., Li, X., Loebenberg, D., et al. (2003). Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14-alpha-demethylase. Antimicrob. Agents Chemother. 47, 577–581. doi:10.1128/AAC.47.2.577-581.2003

Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., and Rodriguez-Tudela, J. L. (2011a). Wild-type MIC distributions and epidemiological cutoff values for azoleresistance in Aspergillus fumigatus species a ubiquitous human fungal pathogen? Med. Mycol. 50, 2979–2983. doi:10.1093/medmycol/myr067

Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., and Rodriguez-Tudela, J. L. (2011b). Azole resistant clinical isolates of Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J. Antimicrob. Chemother. 69, 555–557. doi:10.1093/jac/dkt397

Merkel, J., Yeh, T. C., Elwood, B. M., van der Voort, R. M., and Whitman, J. B. (2010). Multiallele azole resistance Aspergillus fumigatus in the environment in Tanzania. J. Antimicrob. Chemother. 69, 2979–2983. doi:10.1093/jac/dku259

Meylan, H. A., Meis, J. F., Cursos, I. M., Muehlethaler, K., Mouton, J. W., and DePauw, B., Walsh, T. J., Donnelly, P. A., Parmegiani, R. M., Wei, S. Q., Mendrick, C. A., Li, X., Loebenberg, D., et al. (2012). A point mutation in the 14-alpha-sterol demethylase (cyp51A) gene results in reduced susceptibility to itraconazole. J. Clin. Microbiol. 47, 1120–1124. doi:10.1128/AAC.47.3.1120-1124.2003

Nishioka, T., Hattori, Y., Nonomura, K., Tanaka, K., Kato, M., et al. (2009). Prevalence and molecular characterisation of azole resistance in Aspergillus fumigatus isolates from Japanese cystic fibrosis patients. J. Antimicrob. Chemother. 69, 1533–1536. doi:10.1093/jac/dku009
Mellado, E., Garcia-Efron, G., Alcázar-Fuoli, L., Melchers, W. J., Verweij, P. E., Cuenca-Estrella, M., et al. (2007). A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance toazole antifungals involves a combination of cyp51A alterations. *Antimicrob. Agents Chemother.* 51, 1897–1904. doi: 10.1128/AAC.01026-06

Morio, F., Aubin, G. G., Danner-Boucher, I., Haloun, A., Sacchetto, E., Garcia-Hermoso, D., et al. (2012). High prevalence of triazole resistance in *Aspergillus fumigatus*, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. *J. Antimicrob. Chemother.* 67, 1870–1873. doi: 10.1093/jac/dks160

Mortensen, K. L., Jensen, R. H., Johansen, H. K., and Arendrup, M. C. (2010). Environmental study of azole-resistant *Aspergillus fumigatus* and other aspergilli in Austria, Denmark, and Spain. *Antimicrob. Agents Chemother.* 54, 4545–4549. doi: 10.1128/AAC.00692-10

Pfaller, M., Boyken, L., Hollis, R., Kroeger, J., Messer, S., Tendolkar, S., et al. (2011). Use of epidemiological cutoff values to examine 9-year trends in susceptibility of *Aspergillus* species to the triazoles. *J. Clin. Microbiol.* 49, 586–590. doi: 10.1128/JCM.02136-10

Pham, C. D., Reiss, E., Hagen, F., Meis, J. F., and Lockhart, S. R. (2014). Passive surveillance for azole-resistant *Aspergillus fumigatus*, United States, 2011–2013. *Emerg. Infect. Dis.* 20, 1498–1503. doi: 10.3201/eid2009.140142

Piggitano, A., Venier, V., Cogliati, M., De Lorenzis, G., Esposito, M. C., and Tortorano, A. M. (2014). Azole-resistant *Aspergillus fumigatus* in the environment of northern Italy, May 2011 to June 2012. *Euro. Surveill.* 19, 20747. doi: 10.2807/1560-7917.ES2014.19.12.20747

Rath, P. M., Buchheidt, D., Spiess, B., Arfanis, E., Buer, J., and Steinmann, J. (2012). First reported case of azole-resistant *Aspergillus fumigatus* due to the TR/K98H mutation in Germany. *Antimicrob. Agents Chemother.* 56, 6060–6061. doi: 10.1128/AAC.01017-12

Rocchi, S., Daguindau, E., Grenouillet, F., Deconinck, E., Bellanger, A. P., Garcia-Hermoso, D., et al. (2014). Azole-resistant *Aspergillus fumigatus* isolate with the TR34/L98H mutation in both a fungicide-sprayed field and the lung of a hematopoietic stem cell transplant recipient with invasive aspergillosis. *J. Clin. Microbiol.* 52, 1724–1726. doi: 10.1128/JCM.03182-13

Rodriguez-Tudela, J. L., Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Monzon, A., and Cuenca-Estrella, M. (2008). Epidemiological cutoffs and cross-resistance toazole drugs in *Aspergillus fumigatus*. *Antimicrob. Agents Chemother.* 52, 2468–2472. doi: 10.1128/AAC.00156-08

Seyedmousavi, S., Hashemi, S. J., Zibafar, E., Zoll, J., Hedayati, M. T., et al. (2013). Azole-resistant *Aspergillus fumigatus*. Iran. *Emerg. Infect. Dis.* 19, 832–834. doi: 10.3201/eid1905.130075

Sharma, C., Hagen, F., Moroti, R., Meis, J. F., and Chowdhary, A. (2015). Triazole resistant *Aspergillus fumigatus* harbouring G54 mutation: is it de novo or environmentally acquired? *J. Glob. Antimicrob. Resist.* 3, (in press). doi: 10.1016/j.jgar.2015.01.005

Snelders, E., Huys In ’t Veld, R. A., Rijs, A. J., Kema, G. H., Melchers, W. J., and Verweij, P. E. (2009). Possible environmental origin of resistance of *Aspergillus fumigatus* to medical triazoles. *Appl. Environ. Microbiol.* 75, 4053–4057. doi: 10.1128/AEM.00231-09

Snelders, E., van der Lee, H. A., Kuipers, J., Rijs, A. J., Varga, J., Samson, R. A., et al. (2008). Emergence of azole resistance in *Aspergillus fumigatus* and spread of a single resistance mechanism. *PLoS Med.* 5:e219. doi: 10.1371/journal.pmed.0050219

Spiess, B., Postina, P., Reinwald, M., Cornely, O. A., Hamprecht, A., Hoenigl, M., et al. (2014). Incidence of Cyp51A key mutations in *Aspergillus fumigatus*: A study on primary clinical samples of immunocompromised patients in the period of 1995–2013. *PLoS ONE* 9:e103113. doi: 10.1371/journal.pone.0103113

Stensvold, C., Jørgensen, L., and Arendrup, M. (2012). Azole-resistant invasive aspergillosis in HSCT recipients in Germany. *J. Antimicrob. Chemother.* 70, 1522–1526. doi: 10.1093/jac/dks566

Chowdhary et al. Triazole resistant clinical *A. fumigatus*, India